Copyright
©The Author(s) 2018.
World J Gastroenterol. Feb 7, 2018; 24(5): 631-640
Published online Feb 7, 2018. doi: 10.3748/wjg.v24.i5.631
Published online Feb 7, 2018. doi: 10.3748/wjg.v24.i5.631
Table 2 Top ten mutations of PIK3CA and TP53 in this study
| PIK3CA | n (%) | TP53 | n (%) |
| Glu545Lys | 16 (5.1) | Arg175His | 16 (5.1) |
| Glu542Lys | 7 (2.2) | Arg282Trp | 11 (3.5) |
| Val105Ile | 6 (1.9) | Gly245Ser | 9 (2.9) |
| Met1004Ile | 6 (1.9) | Arg248Gln | 9 (2.9) |
| His1047Arg | 6 (1.9) | Arg273His | 8 (2.5) |
| Glu218Lys | 6 (1.9) | Arg273Cys | 7 (2.2) |
| Trp552Ter | 5 (1.6) | Arg248Trp | 7 (2.2) |
| Ser438Phe | 5 (1.6) | Ser260Phe | 6 (1.9) |
| Pro835Leu | 5 (1.6) | Glu358Lys | 6 (1.9) |
| Asp1029Asn | 5 (1.6) | Pro153Ser | 5 (1.6) |
- Citation: Li AJ, Li HG, Tang EJ, Wu W, Chen Y, Jiang HH, Lin MB, Yin L. PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients. World J Gastroenterol 2018; 24(5): 631-640
- URL: https://www.wjgnet.com/1007-9327/full/v24/i5/631.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i5.631